Fisher & Paykel Healthcare Past Earnings Performance
Past criteria checks 5/6
Fisher & Paykel Healthcare's earnings have been declining at an average annual rate of -4.9%, while the Medical Equipment industry saw earnings growing at 8.1% annually. Revenues have been growing at an average rate of 4.5% per year. Fisher & Paykel Healthcare's return on equity is 22.1%, and it has net margins of 20.3%.
Key information
-4.93%
Earnings growth rate
-5.48%
EPS growth rate
| Medical Equipment Industry Growth | 12.30% |
| Revenue growth rate | 4.53% |
| Return on equity | 22.15% |
| Net Margin | 20.30% |
| Last Earnings Update | 31 Mar 2026 |
Recent past performance updates
Recent updates
Narrative Update • Jul 22
FPH: Removal From Conviction List Will Pressure Overvalued Shares
Analysts have revised their fair value estimate for Fisher & Paykel Healthcare to NZ$30.59 from NZ$29.31, citing updated assumptions around discount rates, revenue growth, profit margins and a lower future P/E multiple, and also reflecting the recent removal of the stock from a regional conviction list. What's in the News Fisher & Paykel Healthcare declared a dividend of NZ$0.38823529 per share for the six months ended March 31, 2026, according to company disclosures.
Narrative Update • Jul 08
FPH: Removal From Conviction List Will Meet Higher Dividend Outlook
Analysts have modestly raised the fair value estimate for Fisher & Paykel Healthcare from NZ$46.00 to NZ$47.00, citing updated assumptions on revenue growth, profit margins, and future P/E multiples, along with the stock's recent removal from an APAC Conviction List. What's in the News for Fisher & Paykel Healthcare Fisher & Paykel Healthcare Corporation Limited announced a dividend of NZ$0.38823529 per share for the six months ended March 31, 2026.
Narrative Update • Jun 24
FPH: Stable Dividend And Earnings Outlook Will Support Measured Future Repricing
Analysts have nudged their price target for Fisher & Paykel Healthcare slightly higher to NZ$39.75, reflecting small adjustments to fair value estimates, discount rate, revenue growth, profit margin and expected future P/E assumptions. What's in the News for Fisher & Paykel Healthcare Fisher & Paykel Healthcare declared a dividend of NZ$0.38823529 per share for the six months ended March 31, 2026.Narrative Update • Jun 02
FPH: Strong Earnings And Higher Dividend Will Support Balanced Future Repricing
Analysts have trimmed their price target on Fisher & Paykel Healthcare from NZ$40.59 to NZ$39.63, citing updated assumptions for revenue growth, profit margins, and future P/E multiples. What's in the News Fisher & Paykel Healthcare reported a 14% gain in operating revenue for the 2026 financial year, according to its full year 2026 earnings call highlights.Analysis Article • May 28
Earnings Update: Fisher & Paykel Healthcare Corporation Limited (NZSE:FPH) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
It's been a pretty great week for Fisher & Paykel Healthcare Corporation Limited ( NZSE:FPH ) shareholders, with its...Narrative Update • Apr 23
FPH: Upgraded Guidance And Sector Perform Rating Will Support Bullish Repricing
Analysts have trimmed their fair value estimate for Fisher & Paykel Healthcare by about NZ$0.10 to reflect slightly higher discount rate assumptions, while also acknowledging improved profit margin expectations and recent upgrades in Street price targets, including a move to NZ$36 at one major firm. Analyst Commentary Bullish Takeaways Bullish analysts point to the company’s updated guidance as a key reason for shifting to a more neutral stance, seeing this as support for the revised fair value and the NZ$36 price target.Analysis Article • Apr 18
If EPS Growth Is Important To You, Fisher & Paykel Healthcare (NZSE:FPH) Presents An Opportunity
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Narrative Update • Apr 08
FPH: Refreshed Guidance And Sector Perform Rating Will Shape Measured Future Expectations
Analysts have trimmed the fair value estimate for Fisher & Paykel Healthcare to about NZ$40.69 from NZ$40.89, citing improved company guidance and a higher NZ$36 Street price target as support for the updated view. Analyst Commentary Bullish Takeaways Bullish analysts point to the upgraded company guidance as support for moving to a more neutral stance on the shares, which they see as better aligning expectations with current execution.Narrative Update • Mar 25
FPH: Updated Guidance And Sector Perform Rating Will Shape Balanced Future Expectations
Analysts have trimmed their fair value estimate for Fisher & Paykel Healthcare to NZ$40.89 from NZ$41.12. The modest shift reflects updated assumptions for the discount rate, profit margin and future P/E, following recent guidance and a price target move to NZ$36 from NZ$31 in Street research.Narrative Update • Mar 11
FPH: Refreshed Guidance And Sector Perform Upgrade Will Support Fair Value View
Narrative Update Analysts have lifted their price target for Fisher & Paykel Healthcare to NZ$41.12 from NZ$40.81, citing refreshed guidance and recent Street research that includes an upgrade to Sector Perform with a higher NZ$36 target. Analyst Commentary Bullish analysts see the refreshed guidance as a key reason to reassess Fisher & Paykel Healthcare, with one recent upgrade moving the stock to Sector Perform and lifting the price target to NZ$36 from NZ$31.Narrative Update • Feb 24
FPH: Improved Guidance And Rating Upgrade Will Support Fairly Valued Outlook
Analysts have lifted their NZ$ fair value estimate for Fisher & Paykel Healthcare from NZ$39.15 to NZ$40.81, citing improved company guidance and a recent upgrade in Street price targets as key supports for the higher range of outcomes. Analyst Commentary Bullish Takeaways Bullish analysts see the higher company guidance as a key support for the uplift in fair value to NZ$40.81, suggesting more confidence in the near term earnings outlook than previously reflected in models.Analysis Article • Feb 15
Fisher & Paykel Healthcare Corporation Limited's (NZSE:FPH) Shareholders Might Be Looking For Exit
When close to half the companies in New Zealand have price-to-earnings ratios (or "P/E's") below 18x, you may consider...Narrative Update • Feb 09
FPH: Updated Guidance And Dividend Increase Will Support Fairly Valued Outlook
Analysts have made slight adjustments to their price target for Fisher & Paykel Healthcare, keeping fair value broadly unchanged at about $39.15 per share. They have updated inputs such as the discount rate and assumed future P/E to reflect refreshed views on risk and long-term valuation assumptions.Narrative Update • Jan 26
FPH: Updated Guidance And Dividend Policy Will Support Fairly Valued Returns
Analysts have made only a marginal adjustment to their price target for Fisher & Paykel Healthcare, reflecting small tweaks to assumptions around the discount rate, long term revenue growth, profit margin and future P/E, rather than any major shift in their overall view. What's in the News Fisher & Paykel Healthcare updated full year 2025 guidance, with operating revenue now expected in a range of about $2.17b to $2.27b, compared with the prior range of about $2.15b to $2.25b (Key Developments).Narrative Update • Jan 11
FPH: Dividend And Earnings Guidance Will Support Fairly Valued Future Returns
Analysts have trimmed their price target on Fisher & Paykel Healthcare slightly, citing updated assumptions around discount rate, long run revenue growth, profit margin and future P/E that together point to a fair value of about A$39.15 compared with A$39.33 previously. What's in the News Directors approved an interim dividend of 19.0 cents per ordinary share, compared with 18.5 cents per share in the first half of the prior year, with full New Zealand imputation credit attached (Key Developments).Analysis Article • Dec 18
Here's Why Fisher & Paykel Healthcare (NZSE:FPH) Has Caught The Eye Of Investors
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Narrative Update • Dec 18
FPH: Dividend Increase And Earnings Upgrade Will Support Fair Future Returns
Analysts have slightly raised their price target on Fisher & Paykel Healthcare to $NZD 39.33, reflecting modestly lower discount rate assumptions and a slightly higher future P/E multiple, partly offset by a small downward revision to projected profit margins. What's in the News Directors approved an increased interim dividend of 19.0 cents per ordinary share, up from 18.5 cents in the prior first half, to be paid on 16 December 2025 with a record date of 4 December 2025 (company announcement).Narrative Update • Dec 04
FPH: Dividend Lift And Profit Outlook Will Support Fair Future Returns
Analysts have raised their price target for Fisher & Paykel Healthcare by roughly NZ$2. This reflects expectations of slightly higher long term profitability, modestly lower growth assumptions, and a marginally higher discount rate.Analysis Article • Nov 28
Fisher & Paykel Healthcare Corporation Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Last week saw the newest half-year earnings release from Fisher & Paykel Healthcare Corporation Limited ( NZSE:FPH...Narrative Update • Nov 20
FPH: Fair Value Will Stay Stable Amid Slightly Higher Discount Rate
Analysts have raised their price target for Fisher & Paykel Healthcare from $36.61 to $37.26. They cite slightly higher projected revenue growth along with modest improvements in the profit margin outlook.Analysis Article • Nov 18
At NZ$36.64, Is Fisher & Paykel Healthcare Corporation Limited (NZSE:FPH) Worth Looking At Closely?
Today we're going to take a look at the well-established Fisher & Paykel Healthcare Corporation Limited ( NZSE:FPH...Narrative Update • Nov 05
FPH: Fair Value Assessment Will Remain Steady With Minor Discount Rate Adjustment
Analysts have marginally increased their price target for Fisher & Paykel Healthcare to $36.61. This reflects minor adjustments in company fundamentals and updated discount rate assumptions.Narrative Update • Oct 22
Analysts Hold Price Target for Fisher and Paykel Healthcare as Valuation Inputs Remain Stable
Analysts have maintained their price target for Fisher & Paykel Healthcare at $36.61 per share, citing stable forecasts for discount rate, revenue growth, profit margin, and forward price-to-earnings ratios. Minimal changes were observed in the underlying model inputs.Narrative Update • Oct 08
Aging Demographics And Product Upgrades Will Expand Respiratory Care
Analysts have modestly increased their price target for Fisher & Paykel Healthcare from $36.06 to $36.61 NZD, reflecting updated forecasts for slightly higher revenue growth and improved profitability expectations. Valuation Changes Fair Value Estimate has risen slightly from NZ$36.06 to NZ$36.61 per share.Analysis Article • Oct 07
Be Wary Of Fisher & Paykel Healthcare (NZSE:FPH) And Its Returns On Capital
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Typically, we'll...Narrative Update • Sep 19
Aging Demographics And Product Upgrades Will Expand Respiratory Care
Fisher & Paykel Healthcare's consensus revenue growth and future P/E forecasts both saw only marginal improvements, underpinning the slight increase in the analyst price target from NZ$35.68 to NZ$36.06. What's in the News Fisher & Paykel Healthcare announced an ordinary unfranked dividend of NZD 0.28235294 per share for the six months ended March 31, 2025, payable on July 4, 2025.Analysis Article • Aug 14
Here's Why Fisher & Paykel Healthcare Corporation Limited's (NZSE:FPH) CEO Might See A Pay Rise Soon
NZSE:FPH 1 Year Share Price vs Fair Value Explore Fisher & Paykel Healthcare's Fair Values from the Community and...
New Narrative • Dec 01
New Product Launches And Capacity Expansion Fuel Optimism Amid Margin Pressure And Growth Uncertainty
Diversification with new products and increased manufacturing capacity may drive revenue, but risks include overestimating demand and resulting profit margin pressures.Revenue & Expenses Breakdown
Revenue & Expenses Breakdown
How Fisher & Paykel Healthcare makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 26 | 2,308 | 469 | 598 | 236 |
| 31 Dec 25 | 2,233 | 453 | 579 | 233 |
| 30 Sep 25 | 2,158 | 437 | 559 | 231 |
| 30 Jun 25 | 2,090 | 407 | 547 | 229 |
| 31 Mar 25 | 2,021 | 377 | 534 | 227 |
| 31 Dec 24 | 1,956 | 278 | 526 | 219 |
| 30 Sep 24 | 1,890 | 179 | 517 | 211 |
| 30 Jun 24 | 1,817 | 156 | 505 | 205 |
| 31 Mar 24 | 1,743 | 133 | 493 | 198 |
| 31 Dec 23 | 1,719 | 197 | 480 | 193 |
| 30 Sep 23 | 1,694 | 262 | 466 | 187 |
| 30 Jun 23 | 1,638 | 256 | 449 | 181 |
| 31 Mar 23 | 1,581 | 250 | 432 | 174 |
| 31 Dec 22 | 1,527 | 251 | 419 | 168 |
| 30 Sep 22 | 1,472 | 251 | 406 | 163 |
| 30 Jun 22 | 1,577 | 314 | 399 | 158 |
| 31 Mar 22 | 1,682 | 377 | 393 | 154 |
| 31 Dec 21 | 1,821 | 449 | 396 | 151 |
| 30 Sep 21 | 1,961 | 521 | 398 | 148 |
| 30 Jun 21 | 1,966 | 522 | 397 | 142 |
| 31 Mar 21 | 1,971 | 524 | 397 | 137 |
| 31 Dec 20 | 1,787 | 458 | 380 | 133 |
| 30 Sep 20 | 1,603 | 392 | 363 | 129 |
| 30 Jun 20 | 1,433 | 339 | 351 | 124 |
| 31 Mar 20 | 1,264 | 287 | 338 | 119 |
| 31 Dec 19 | 1,197 | 260 | 327 | 114 |
| 30 Sep 19 | 1,130 | 233 | 316 | 109 |
| 30 Jun 19 | 1,100 | 221 | 310 | 105 |
| 31 Mar 19 | 1,070 | 209 | 304 | 100 |
| 31 Dec 18 | 1,052 | 208 | 302 | 97 |
| 30 Sep 18 | 1,034 | 206 | 299 | 94 |
| 30 Jun 18 | 1,007 | 198 | 295 | 94 |
| 31 Mar 18 | 981 | 190 | 291 | 95 |
| 31 Dec 17 | 954 | 181 | 289 | 93 |
| 30 Sep 17 | 928 | 172 | 287 | 91 |
| 30 Jun 17 | 911 | 171 | 278 | 89 |
| 31 Mar 17 | 894 | 169 | 269 | 86 |
| 31 Dec 16 | 877 | 164 | 263 | 83 |
| 30 Sep 16 | 860 | 160 | 256 | 79 |
| 30 Jun 16 | 838 | 152 | 249 | 76 |
| 31 Mar 16 | 815 | 143 | 242 | 73 |
| 31 Dec 15 | 776 | 135 | 223 | 71 |
| 30 Sep 15 | 736 | 126 | 203 | 69 |
Quality Earnings: FPH has high quality earnings.
Growing Profit Margin: FPH's current net profit margins (20.3%) are higher than last year (18.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: FPH's earnings have declined by 4.9% per year over the past 5 years.
Accelerating Growth: FPH's earnings growth over the past year (24.2%) exceeds its 5-year average (-4.9% per year).
Earnings vs Industry: FPH earnings growth over the past year (24.2%) exceeded the Medical Equipment industry 22.5%.
Return on Equity
High ROE: FPH's Return on Equity (22.1%) is considered high.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/06 17:05 |
| End of Day Share Price | 2026/08/06 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Fisher & Paykel Healthcare Corporation Limited is covered by 23 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Saul Hadassin | Barrenjoey Markets Pty Limited |
| Lyanne Harrison | BofA Global Research |
| Shane Storey | Canaccord Genuity |